186 related articles for article (PubMed ID: 32713439)
1. Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer?
Kelly KN; Macedo FI; Merchant NB
Adv Surg; 2020 Sep; 54():49-68. PubMed ID: 32713439
[No Abstract] [Full Text] [Related]
2. Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Cunningham SC; Cusnir M; Burdick RK; Van Echo DA; Moesinger R
Clin Adv Hematol Oncol; 2003 Dec; 1(12):741-2; discussion 743. PubMed ID: 16258479
[No Abstract] [Full Text] [Related]
3. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
[TBL] [Abstract][Full Text] [Related]
4. Treatment of borderline resectable pancreatic cancer.
Cooper AB; Tzeng CW; Katz MH
Curr Treat Options Oncol; 2013 Sep; 14(3):293-310. PubMed ID: 23793524
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
[TBL] [Abstract][Full Text] [Related]
6. A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy.
Neofytou K; Giakoustidis A; Smyth EC; Cunningham D; Mudan S
J Surg Oncol; 2015 May; 111(6):768-70. PubMed ID: 25556724
[TBL] [Abstract][Full Text] [Related]
7. Multimodality management of borderline resectable pancreatic adenocarcinoma.
Prakash LR; Katz MHG
Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
[TBL] [Abstract][Full Text] [Related]
8. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
9. Novel directions in neoadjuvant therapy for pancreas adenocarcinoma.
Yang A; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):585-601. PubMed ID: 25686370
[TBL] [Abstract][Full Text] [Related]
10. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.
Katz MH; Pisters PW; Evans DB; Sun CC; Lee JE; Fleming JB; Vauthey JN; Abdalla EK; Crane CH; Wolff RA; Varadhachary GR; Hwang RF
J Am Coll Surg; 2008 May; 206(5):833-46; discussion 846-8. PubMed ID: 18471707
[TBL] [Abstract][Full Text] [Related]
11. New developments in the management of borderline resectable pancreatic cancer.
Sharma J; Ng J; Goodman MD; Saif MW
JOP; 2013 Mar; 14(2):123-5. PubMed ID: 23474551
[TBL] [Abstract][Full Text] [Related]
12. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
13. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
14. Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
Am Surg; 2022 Dec; 88(12):2899-2906. PubMed ID: 33861651
[TBL] [Abstract][Full Text] [Related]
15. Management of Borderline Resectable Pancreatic Cancer.
Toesca DAS; Koong AJ; Poultsides GA; Visser BC; Haraldsdottir S; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1155-1174. PubMed ID: 29722658
[TBL] [Abstract][Full Text] [Related]
16. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.
Gilbert JW; Wolpin B; Clancy T; Wang J; Mamon H; Shinagare AB; Jagannathan J; Rosenthal M
Ann Oncol; 2017 Sep; 28(9):2067-2076. PubMed ID: 28407088
[TBL] [Abstract][Full Text] [Related]
17. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant interferon-based chemoradiation for borderline resectable and locally advanced pancreas cancer: a Phase II pilot study.
Jensen EH; Armstrong L; Lee C; Tuttle TM; Vickers SM; Sielaff T; Greeno EW
HPB (Oxford); 2014 Feb; 16(2):131-9. PubMed ID: 23509924
[TBL] [Abstract][Full Text] [Related]
19. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
[TBL] [Abstract][Full Text] [Related]
20. Active Systemic Treatment of Pancreatic Cancer.
Tempero M
J Natl Compr Canc Netw; 2017 May; 15(5S):723-725. PubMed ID: 28515255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]